Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Joyce O’Shaughnessy, MD, Sarat Chandarlapaty, MD, PhD, Mitchell Elliott, MD, FRCPC, and Seth A. Wander, MD, PhD, discuss how they are integrating recent data from pivotal clinical trials evaluating next-generation oral selective estrogen receptor degraders (SERDs) as well as inhibitors of the PI3K/AKT/mTOR signaling pathway into the management of patients with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC), using a variety challenging clinical scenarios to draw out insights and clinical pearls.

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Lilly; Rigel Pharmaceuticals; and Stemline Therapeutics, Inc.

Seth A. Wander, MD, PhD

Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Massachusetts General Hospital
Boston, MA

Disclosures: Advisor, Consultant, Fee for Service Recipient: Arvinas, AstraZeneca, Biovica, Boundless Bio, Celcuity, Delcath, Eli Lilly, Foundation Medicine, Genentech, Gilead, Halda Therapeutics, Hologic, Novartis, Pfizer, Puma Biotechnology, Regor Therapeutics, Stemline/Menarini, Veracyte; Grant/Research Funding: Arvinas, Eli Lilly, Genentech, Nuvation Bio, Pfizer, Phoenix Molecular Designs, Puma Biotechnology, Regor Therapeutics, Sermonix, Stemline/Menarini

Sarat Chandarlapaty, MD, PhD

Naddisy Foundation Chair in Breast Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer

Mitchell Elliott, MD, FRCPC

Lecturer, Medical Oncology
Medical Oncologist, Clinician Scientist
Yale Cancer Center, Yale New Haven Health
New Haven, CT

Disclosures: Advisor, Consultant, Fee for Service Recipient: Gilead, Knight Therapeutics, Roche

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX

Disclosures: Advisor, Consultant, Fee for Service Recipient: AADI Bioscience, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, BioNTech, Bristol Myers Squibb, Daiichi Sankyo, Duality, Eisai, Eli Lilly, Ellipses, Exact Sciences, G1 Therapeutics, Genentech, Gilead Sciences, Guardant Health, HiberCell, Jazz, Johnson & Johnson, Menarini-Stemline, Merck, Mersana, Natera, Novartis, Pfizer, Pierre Fabre, Puma Biotechnology, RayzeBio, Roche, Sanofi, Seagen, Stemline Therapeutics, Summitt Therapeutics, Tempus, TerSera Therapeutics

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the key data from pivotal clinical trials of the oral SERDs and the PI3K/AKT/mTOR pathway inhibitors in patients with HR+/HER2- mBC, go to https://www.gotoper.com/ibc26hrmbc-activity.

Release Date

September 28, 2026

Expiration Date

September 28, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.